Search results

This paper analyses and assesses the effect of firm-specific determinants (FSDs) on supply-chain performance (SCP) and export performance (EP). It examines SCP’s influence on EP and its mediating effect on the relationship between FSD and EP.

This paper develops a theoretical framework based on the resource-based view (RBV) and dynamic-capability theory to understand SCP’s role in the FSD-EP link while empirically validating using the Indian automobile industry segments (IAIS) data. The sample frame comprises all listed firms in IAIS between the financial year 2010-11 and 2021–22, with continuous data availability throughout the considered timeline. The paper employs factor analysis for dimension reduction, a panel-data-fixed-effect model to analyze the relationships, bootstrap to test the mediation effect and focus-group discussion for validating the results obtained through statistical analyses.

FSD directly influences SCP’s efficiency aspect and EP. Distribution efficiency and inventory efficiency characteristics of SCP directly impact EP and completely mediate the relationship between FSD and EP.

This study provides significant insights into how firms can increase EP by focusing on firm-specific and SCP-related factors. To improve EP, firms should concentrate on enhancing distribution and inventory efficiencies. Firms must focus on critical firm-level factors like age, size and raw-material import capability to increase their ability to solve SC-specific barriers and improve SCP, resulting in enhanced exports.

This study investigates the impacts of FSD on SCP and EP and examines the mediating effect of SCP on the relationship between FSD and EP. Such a mediating role of SCP has rarely been probed in the literature.

Pharmaceutical industry involves highly specialized business processes where strong research and development focus along with market differentiation and localization are the deciders of success. This has led to evolution of segments and complexities in supply chain. This paper aims to focus on segmental differences in supply chain performance of Indian Pharmaceutical firms.

This paper measures supply chain performance of select segmental players of the pharmaceutical industry using financial metrics and supply chain operations reference (SCOR) key performance indicators through a five-year timeline. The best performance results are compared across the segments to identify unique performance features, if any. The sample results are validated through hypothesis testing methodology.

This paper has evidenced that the innovators segment is performing better in cash-to-cash cycle time and supply chain working capital productivity, whereas generics segment is doing better in distribution cost efficiency and total cost to serve aspects.

The paper is based on historical financial data of firms and measures the firm focused supply chain performance. The results may not be generalized in a global context but serve as a motivator for other researchers to take similar studies. The paper may further be analyzed with primary data of the firms to understand the segmental difference in customer focus supply chain performance measures.

This paper has brought out important segmental supply chain performance features of the Indian pharmaceutical firms and identified segment-specific problems by integrating SCOR KPIs and financial metrics.

This paper has integrated both SCOR KPIs and financial metrics to provide unique insights on segmental differences in the performance behavior of pharmaceutical supply chain.